Answers are grounded in this paper and cite their sources.
Radiometal-labeled porphyrin derivatives have emerged candidates for targeted brain tumor imaging and therapy. In this study, we synthesized a boronic-acid-conjugated porphyrin and radiolabeled it with 64 Cu to evaluate its dual-function potential for PET imaging and boron neutron capture therapy (BNCT). The 64 Cu-labeled 5,10,15,20-(tetra-4-dihydroxyborylphenyl)porphyrin ([ 64 Cu]Cu-TDBP) exhibited excellent serum stability and significant uptake in U87MG cells. PET imaging in both xenograft and orthotopic models demonstrated time-dependent tumor accumulation, with selective localization in the brain tumor at 18 h post-injection (p.i.). The tumor-to-brain ratio increased from 7.2 at 4 h p.i. to 26.3 at 18 h p.i., alongside a rise in tumor boron concentration from 0.79 to 1.83 ppm over the same period. These results highlight the potential of [ 64 Cu]Cu-TDBP as a promising theranostic agent for precise brain tumor imaging and effective BNCT.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: